We thought that these statistics might be useful to consider as you strive to make or update your own workplace drug policies.

This NSC survey was taken by over 500 individuals that make decisions about workplace drug and alcohol programs for their companies. While 86% of the respondents agreed that opioids (even while taken as prescribed) impact job performance, only half (50%) of respondents felt confident about their company’s substance abuse policies and procedures.

Some other interesting statistics from the survey included:

-75% of employers have been directly affected by opioid use
-79% of employers are not very confident that individual employees can spot warning signs of opioid misuse
-One-third of employers have experienced an overdose, arrest, or injury/near-miss
-38% of employers have experienced absenteeism or impaired worker performance
–Despite widespread impact, only 17% of employers feel extremely well prepared to deal with this issue

Nick Smith, interim president and CEO of NSC said, “The opioid crisis is truly encompassing nearly every aspect of American lives. Today’s survey confirms that the No. 1 cause of preventable death is not just taking its toll on our home lives but companies across the country are also grappling with the impact of this epidemic.”

If you have questions about reasonable suspicion training or how you can help get your supervisors trained to handle drug and alcohol abuse within the workplace, please contact us! We’ll help you get it figured out. All Blueline Service clients have access to our FREE reasonable suspicion training materials.

You can contact our drug testing department at mail@blueline-services.com. Please feel free to take a look at NSC’s drug use guide as well here.

The post Employers Speak Up About Illicit Opioid Use At Work appeared first on Blueline.

New laws legalizing recreational marijuana and shifting attitudes towards drugs make many hesitant to believe the failed drug test rate will drop anytime soon. Barry Sample, the senior director of science and technology for Quest Diagnostics said, “It’s unfortunate that we mark 30 years of the Drug-Free Workplace Act with clear evidence that drugs continue to invade the country’s workplaces. Not only have declines appeared to have bottomed out, but… in some drug classes and areas of the country drug positivity rates are increasing.”

Some key findings from the 2018 Drug Testing Index include the following:

• Cocaine: This will be the fifth consecutive year that positivity rates for cocaine have increased. Certain states have even seen a double-digit increases during these years for cocaine positivity rates. Nebraska saw a 91% percent increase between 2016 and 2017, Idaho (88% increase), Washington (31%), Nevada (25%), Maryland (22%), and Wisconsin showed a 13% increase.

• Methamphetamine: Over the last 4 years, methamphetamine positivity has skyrocketed across the U.S.—particularly in the midwest and southern states. With 21 states having experienced 140-167% increase in positivity. Some of the states with the largest increases include: Illinois, Indiana, Michigan, Ohio, Wisconsin, Alabama, Kentucky, Mississippi, Tennessee, New Jersey, New York and Pennsylvania.

• Marijuana: For the past 5 years, marijuana has seen a steady increase of 4% for failed drug tests, including a nearly 8% increase in safety-sensitive workplaces. The largest increases for failed drug tests in this past year have appeared in states that have now legalized marijuana. These states include: Nevada (39% increase), California (20%), and Massachusetts (11%). The Drug Testing Index also showed that almost half (45%) of all workers with positive tests included some evidence of marijuana.

• Opioid: The large-scale fight against prescription opioid abuse for the past few years seems to be paying off with a 17% decrease from 2016 to 2017. This is a dramatic decline that put opioid specific use, other than codeine, at its lowest positivity rate in more than a decade.

• Heroin: Other good news showed that heroin positivity has decreased to a 3 year low – which marked almost an 11% decrease.

Sample said this is the first time they have seen such a broad increase across drug types. The decline in opioids shows a strong step forward, but overall rates are still remaining high. The increased workplace drug rates don’t seem to come as much of a surprise though, with the increase in marijuana use being more than expected.

“These increases are similar to the increases we observed after recreational use statues were passed in Washington and Colorado. While it is too early to tell if this is a trend, our data suggests that the recreational use of marijuana is spilling into the workforce, including among individuals most responsible for keeping our communities safe.”

it’s more important now than ever to understand the signs of substance abuse and be qualified to report such abuse in the workplace.

While it’s not completely clear what is causing this sustained increase in drug use at the workplace,it’s more important now than ever to understand the signs of substance abuse and be qualified to report such abuse in the workplace.

The post Workplace Drug Positivity At Highest Rate In A Decade appeared first on Blueline.

Hydromorphone, hydrocodone, oxymorphone and oxycodone are all being added to the new drug-testing panel.

This means that beginning in 2018, all drivers will now be tested for these four commonly abused opioids. Opioid abuse has risen dramatically in recent years, with drug overdose deaths nearly tripling—a large percentage being attributed to opioids, according to CDC statistics.

“Inclusion of these four semi-synthetic opioids is intended to help address the nationwide epidemic of opioid abuse,” the DOT said in its rulemaking notice which will be officially published in the Federal Register on Monday (11/13).

In addition to these four opioids, the DOT will also remove methylenedioxyethylamphetamine (MDEA) from the existing drug testing panel and add methylenedioxyamphetamine (MDA).

“The opioid crisis is a threat to public safety when it involves safety-sensitive employees involved in the operation of any kind of vehicle or transport,” said Secretary Elaine L. Chao. “The ability to test for a broader range of opioids will advance transportation safety significantly and provide another deterrence to opioid abuse, which will better protect the public and ultimately save lives.”

This ruling will be effective starting January 1, 2018. 

The post Opioid Epidemic brings new DOT drug testing panel appeared first on Blueline.